

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/926,256	10/02/2001	Naoyuki Fukuchi	214595US0PCT	8955		
22850	7590 11/26/2003		EXAM	INER		
,	PIVAK, MCCLELLAND,	SNEDDEN, SHERIDAN				
1940 DUKE STREET ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER		
	•		1653			
				DATE MAILED: 11/26/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Anni	ication No.	Applicant(s)			
Office Action Summary							
			26,256	FUKUCHI ET AL.			
			niner	Art Unit			
			idan K Snedden	1653			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Poriod for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
1)	Responsive to communication(s) file	ed on					
2a) <u></u> □	This action is <b>FINAL</b> . 2b) This action is non-final.						
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)🖂	4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.						
	4a) Of the above claim(s) <u>none</u> is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)[	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)🖾	8) Claim(s) 1-15 are subject to restriction and/or election requirement.						
Applicati	on Papers						
9)[	The specification is objected to by th	e Examiner.					
10)[	The drawing(s) filed on is/are:	: a) ☐ accepted o	or b) objected to by the E	xaminer.			
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. §§ 119 and 120							
a)[ * S 13)	Acknowledgment is made of a claim All b) Some * c) None of:  1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internation ee the attached detailed Office action cknowledgment is made of a claim force a specific reference was included of the certified copies application from the foreign large of the certified copies application from the foreign large of the certified copies application of the foreign large of the certified copies application of the foreign large of the certified copies application of the foreign large of the certified copies application of the foreign large of the certified copies application of the foreign large of the certified copies application from the foreign large of the certified copies of the priority application from the attached copies application from the linear priority application from the certified copies application from the certified copies application from the certified copies application from the copies application from the certified copies application from the certifi	documents have documents have of the priority document for all stream for a list of the fordomestic priorical din the first sentenguage provisions or domestic priorical domestic priori	been received. been received in Application cuments have been received. Rule 17.2(a)). certified copies not received ty under 35 U.S.C. § 119(elence of the specification or all application has been received ty under 35 U.S.C. §§ 120 at the specification of the specification or all application has been received the specification of the specification has been received the specification of the specification has been received the specification has been received the specification of the specification has been received the specification has been received the specification of the specification has been received the specification of the specificati	on No d in this National Stage d. ) (to a provisional application) in an Application Data Sheet. eived. and/or 121 since a specific			
Attachment(s)							
2) D Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (P nation Disclosure Statement(s) (PTO-1449) P			PTO-413) Paper No(s) stent Application (PTO-152)			

## DETAILED ACTION

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-10, drawn to a method of producing a subunit peptide.

Group II, claim(s) 11-15, drawn to a subunit peptide.

2. Upon thorough consideration of the claims, the examiner has determined that a lack of unity of invention exists, as defined in Rule 13.

PCT Rule 13.2 states that unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. Annex B, Part 1(b), indicates that "special technical features" means those technical features which as a whole define a contribution over the prior art. The inventions listed as Groups I and II are directed to a subunit peptide from snake venom that inhibits binding from von Willebrand factor to a platelet and the method of producing such a peptide. These inventions share the common special technical feature of a subunit peptide that inhibits binding from von Willebrand factor to a platelet. This common special technical feature is not a contribution over the prior art as it is taught by Fukuchi *et al.* (US 5856126 A). Thus the invention of Groups I and II lack unity of invention.

Application/Control Number: 09/926,256

Art Unit: 1653

## Advisory Information

Page 3

3. A telephone call was made to Daniel J. Pereira on November 12, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan K Snedden whose telephone number is (703) 305-4843. The examiner can normally be reached on Monday - Friday, 8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone number for regular communications to the organization where this application or proceeding is assigned is (703) 746-3975.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SKS November 18, 2003

SYS

KAREN COCHRANE CAPLSON, PH.D
PRIMARY EXAMINER